Unknown

Dataset Information

0

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study.

ABSTRACT:

SUBMITTER: Deodhar A 

PROVIDER: S-EPMC9704810 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study.

Deodhar Atul A   Chakravarty Soumya D SD   Shiff Natalie J NJ   Lo Kim Hung KH   Xu Stephen S   Hsia Elizabeth C EC   Danve Abhijeet A   Reveille John D JD  

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20220602 8

Similar Datasets

Unknown Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.
| S-EPMC7497341 | biostudies-literature
Unknown Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study.
| S-EPMC9336574 | biostudies-literature
Unknown Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
| S-EPMC10326229 | biostudies-literature
Unknown Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.
| S-EPMC4392310 | biostudies-literature
Unknown Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab.
| S-EPMC5943646 | biostudies-literature
Unknown Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
| S-EPMC8935699 | biostudies-literature
Unknown Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
| S-EPMC6329737 | biostudies-literature
Unknown Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.
| S-EPMC5696295 | biostudies-literature
Unknown Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
| S-EPMC5192572 | biostudies-literature
Unknown Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab.
| S-EPMC3329231 | biostudies-literature